Sotorasib, Infigratinib, And More
Jun 03, 2021•14 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Two new drugs approved in the last week:
1. sotorasib, a drug for a specific KRAS mutation (G12C) in 2nd line metastatic NSCLC
2. infigratinib, basically a "me too" FGFR inhibitor approved for metastatic cholangiocarcinoma
We all discuss the latest adjuvant CHECKMATE study (nivolumab in urothelial carcinoma) and a recent study of seropositivity in cancer patients following COVID vaccination.
For the best experience, listen in Metacast app for iOS or Android